Explore All 3115 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | June 17, 2025 |
| Target | Verve Therapeutics |
| Sector | Life Science |
| Buyer(s) | Lilly |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.3B USD |
| Advisor(s) | Centerview Partners Guggenheim Securities (Financial) Paul, Weiss, Rifkind, Wharton & Garrison (Legal) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 45.0B USD (2024) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. The company's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| Deal Context for Buyer | # |
|---|---|
| Overall | 37 of 38 |
| Sector: Life Science | 30 of 31 |
| Type: Add-on Acquisition | 29 of 30 |
| State: Massachusetts | 9 of 9 |
| Country: United States | 32 of 33 |
| Year: 2025 | 3 of 4 |
| Size (of disclosed) | 8 of 21 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-05-27 |
SiteOne Therapeutics
South San Francisco, California, United States SiteOne Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of highly selective small-molecule inhibitors targeting Nav1.7, Nav1.8, and other ion channels to treat pain, cough, and other conditions involving hyperexcitability of the peripheral nervous system. SiteOne Therapeutics is based in South San Francisco, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-24 |
Adverum
Redwood City, California, United States Adverum is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Adverum Biotechnologies was founded in 2006 and is based in Redwood City, California. |
Buy | - |
